Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Dental, Vision, and Hearing Inclusion in Senior Protection. - 2AstraZeneca to invest $2 billion as part of US manufacturing push
- 3Mobility exercises are an important part of fitness as we age. Here are some tips
- 4Step by step instructions to Look at Compact disc Rates: A Thorough Aide
- 5Former ‘Dancing with the Stars’ Pro Survives Plane Crash at LaGuardia That Left 2 Pilots Dead
- Scientists Just Discovered Japan’s First New Bird Species in Over 40 Years
- Four Dead in Last Month From Animal Attacks in Nepal
- Russia Establishing Long-Range Drone Bases In Belarus, Warns Ukraine
- The Response to Fake General Knowledge: Investigating the Eventual fate of artificial intelligence
- NASA’s Artemis II mission will take an astronaut crew around the Moon – a space policy expert describes the long road to launch
- Geminid meteor shower, one of the year's most reliable, peaks this weekend
- Mexican Woman Accused of Assaulting Partner With Belt After He Refused Sex, Police Say
- Agios Pharma shares jump as US FDA expands approval for its blood disorder drug
- Why are malnutrition deaths soaring in America?
